Comfrey

Symphytum officinale is a robust perennial in the Boraginaceae, native to Europe and western Asia and naturalized in parts of North America. It favors damp ground: riverbanks, ditches, wet meadows, and garden edges with rich soil. Plants form clumps from a thick, dark, fleshy taproot that snaps with a cucumber-like scent when fresh. Stems are winged and bristly. Leaves are large, lance-shaped to ovate, roughly hairy, and distinctly veined; basal leaves can be a foot long. Flowers hang in coiled cymes (scorpioid), typically dull purple, mauve, or creamy white, each a small drooping bell with a closed throat of scales—classic borage-family architecture.

Identity matters because “comfrey” in commerce is not one chemotype. Common comfrey (S. officinale) is the pharmacopeial species in older European texts. Prickly comfrey (S. asperum) and, especially, Russian comfrey (S. × uplandicum, the hybrid of S. officinale and S. asperum) are widely grown as fodder and compost plants. The hybrid is vigorous, often taller, and frequently higher in certain PAs such as echimidine. Gardeners who grow “bocking” clones for fertilizer tea are often growing the hybrid, not official common comfrey. A leaf from the compost pile is not a characterized drug.

Look-alikes include other bristly Boraginaceae and, in name only, boneset (Eupatorium perfoliatum), an unrelated aster that has caused its own confusion in English herbals. True comfrey has succulent, mucilaginous roots and nodding tubular flowers, not the perfoliate leaves of boneset.

The parts historically used are dried root (Symphyti radix) and aerial herb (leaf and flowering tops). Roots tend to be richer in allantoin and also carry PAs; young leaves were the folk poultice. PA concentration varies by species, plant part, age, season, and drying. Roots and young leaves can be particularly problematic. There is no kitchen assay for “how much lycopsamine is in this clump.”

Allantoin is a hydantoin derivative also found in other plants and in some cosmetic urea-related pathways; it is associated with keratolytic and cell-proliferation folklore. Rosmarinic acid is a phenolic that appears in anti-inflammatory models. Mucilage soothes. None of those constituents cancel the PA problem. They explain why people wanted the plant on skin. They do not make the liver safe.

Comfrey’s European trail is long and orthopedic in spirit. Dioscorides and later medieval authors discussed Symphytum-type plants for knitting wounds and closing tissues—the Greek root of the genus name is often linked to “grow together.” Country practice wrapped mashed leaf around sprains and used root decoctions internally for ulcers, “blood in the spit,” and bowel complaints. The English knitbone and consound names advertise that mechanical metaphor: a plant that glues what is broken.

Nineteenth- and early twentieth-century pharmacy still listed comfrey root. Then toxicology caught up. Unsaturated PAs were characterized across the Boraginaceae, Asteraceae, and Fabaceae. Case reports of hepatic veno-occlusive disease after comfrey tea and tablets accumulated from the 1970s onward—some in people who thought they were taking a gentle ulcer remedy. The lesions resemble those from other PA plants (for example, certain Crotalaria and Senecio exposures): occlusion of small hepatic veins, hepatomegaly, ascites, and, in severe cases, liver failure.

Regulatory history is unusually clear for an herb. In 2001 the U.S. FDA advised dietary-supplement firms to remove comfrey products intended for internal use because of PA hepatotoxicity and the lack of a demonstrated safe oral dose. Several European authorities restricted or removed oral comfrey medicines. Germany’s Commission E had already limited official use to external application for bruises, strains, and sprains. The European Medicines Agency’s herbal assessment later framed traditional topical use on intact skin, with duration limits, exclusion of broken skin, and exclusion of pregnancy, lactation, and children in the conservative documents.

Meanwhile, manufacturers developed PA-reduced or “PA-free” topical extracts—often from S. × uplandicum clones selected and processed to strip alkaloids—used in ointments studied for back pain and ankle sprain. Those products are not equivalent to a mashed garden leaf. They are also not proof that unlimited DIY poultice is safe, because skin is not a perfect barrier and broken skin is a worse one.

Comfrey never left the permaculture garden. Dynamic-accumulator folklore (mining potassium and silica for compost) is a horticultural story, not a dietary one. “Comfrey fertilizer tea” for tomatoes is not a beverage. That distinction still gets lost when the same plant is discussed as medicine.

Two pharmacologies run in parallel, and only one of them is the reason comfrey is famous. Allantoin can promote epithelial proliferation and a moist wound environment in experimental and cosmetic contexts. Rosmarinic acid and other phenolics show anti-inflammatory and analgesic signals in models and in some topical human studies. Mucilage is demulcent. Together they make a coherent story for rubbing a PA-reduced ointment onto a bruise or strained muscle: less soreness, perhaps faster comfort, without claiming that a bone has “knitted” because of a leaf.

The other pharmacology is PA toxicity. Unsaturated pyrrolizidine alkaloids such as lycopsamine, intermedine, symphytine, and—especially in some Russian comfrey material—echimidine are absorbed and oxidized, largely via CYP3A4, to pyrrolic esters. Those electrophiles bind proteins and DNA in hepatocytes and sinusoidal endothelial cells. Repeated exposure is cumulative. The clinical picture of hepatic sinusoidal obstruction syndrome (older term: veno-occlusive disease) includes abdominal pain, hepatomegaly, ascites, and abnormal liver tests. Pulmonary hypertension and other endothelial injuries appear in the broader PA literature. Carcinogenicity in animals is part of why regulators refuse a “safe daily tea.”

Absorption from intact skin is lower than from the gut, which is the rationale for allowing short topical courses. Absorption from damaged skin, mucous membranes, or large areas is higher. Occlusive wraps, heat, and daily use for weeks all push exposure up. Children have smaller bodies and developing livers. There is no established oral NOAEL for garden comfrey that would make a folk tea acceptable.

PA-reduced extracts used in European trials are not “the whole plant minus the bad part” in a folk sense. They are processed drugs with specified residual alkaloid limits. A homegrown poultice has unspecified PAs, unspecified allantoin, and unspecified dirt.

Comfrey does not set fractures. Imaging, reduction, and immobilization set fractures. At best, a studied ointment may ease periarticular soreness after a sprain already evaluated as not needing surgery. Using a poultice to “wait and see” on a possible break is how malunion happens.

Traditional external uses are bruises, contusions, strains, sprains, and localized muscle or joint pain after minor trauma. Commission E and later EMA-style documents still point at that cluster. Randomized trials of specific PA-reduced comfrey ointments (including products studied for acute ankle sprain and upper or lower back pain) have reported greater pain reduction and functional improvement versus placebo over days to a couple of weeks. Those trials do not validate every cottage salve, every species, or internal use.

Traditional internal uses—gastric and duodenal ulcer folklore, lung complaints, diarrhea, heavy menstrual bleeding—are historically real and clinically obsolete. Oral comfrey is not an evidence-based ulcer therapy. It is a documented cause of liver injury. Do not treat dyspepsia with comfrey tea because a Victorian herbal said so.

Bone healing is the most stubborn myth. The knitbone name and allantoin’s cell-proliferation story got collapsed into “comfrey mends fractures.” There is no good clinical evidence that topical or oral comfrey replaces orthopedic care. Reducing swelling around a sprain is not the same as osteogenesis.

Cosmetic creams sometimes include comfrey or allantoin for dry or irritated skin. Concentration and PA specification vary. A face cream is still a dermal exposure; it is not a reason to use root poultice on dermatitis or eczema that has broken the barrier.

Comfrey is not a treatment for cancer, hepatitis, or “liver detox”—the last of those is grimly ironic. It is not a substitute for NSAIDs in rheumatoid disease, though people with chronic back pain sometimes see topical trial data and over-generalize. Persistent or worsening pain, numbness, fever, or inability to bear weight needs a clinician, not a thicker poultice.

Historical preparations include fresh-leaf poultices, root decoctions, ointments, and, disastrously, teas and tablets for internal use. Modern responsible commerce, where it still exists, is almost entirely topical: creams and ointments, preferably specified as PA-reduced or PA-free, labeled for intact skin and short duration.

European traditional herbal posology for topical comfrey is conservative: apply to unbroken skin, limited daily area, limited consecutive days (assessment reports often discuss on the order of two to three weeks, not open-ended use), and stop if the skin barrier fails. Follow the actual product label. Do not improvise a week-long body wrap.

Garden preparations are the quality failure mode. Wilted leaves from S. × uplandicum, unwashed roots, and “comfrey oil” macerated in a jar have unknown alkaloid loads. Infused oils left at room temperature also have a contamination story separate from PAs.

Do not make tea, tincture for swallowing, capsules, or “ulcer syrup” from any Symphytum. Do not add comfrey to smoothie greens. Do not assume drying or cooking destroys PAs to a safe level—the toxicology literature does not give home cooks that out.

If a clinician or pharmacist points you to a licensed topical product, that is a different object from the plant in the ditch. Species, extract, residual PA specification, and duration are the variables that made trials possible.

Topical PA-reduced ointments in trials were generally locally well tolerated; contact dermatitis, itching, or redness can occur. Allergy to Boraginaceae is possible. Applying to broken skin increases both irritation and systemic PA absorption.

Oral or excessive use is the serious category. Hepatic sinusoidal obstruction syndrome may present with right-upper-quadrant pain, swelling of the abdomen, rapid weight gain from fluid, jaundice, or unexplained fatigue. Liver enzymes and bilirubin can rise. Onset may be subacute after repeated teas or tablets rather than a single dramatic poisoning. Pulmonary symptoms appear in some PA-exposure series. This is not “a little stomach upset from a bitter root.”

Because PA injury is cumulative, people who used comfrey for months as a “gut healer” are the classic case reports—not only a one-time mistake. There is no antidote in the herbal sense; management is medical, and severe disease can require transplant in the worst PA epidemics from other plants.

Animal data and genotoxicity of PA pyrroles are why regulators will not define a recreational oral dose. “I feel fine” does not mean the sinusoids are fine.

NCCIH, MedlinePlus, and FDA consumer materials all treat internal comfrey as unsafe. That consensus is stronger than for most herbs on this site. Treat disagreement on internet forums as noise.

Do not take comfrey by mouth in any form. That includes tea, tincture, capsules, and “only a little in a blend.” There is no demonstrated safe internal dose of PA-containing Symphytum.

Do not use topical comfrey on broken skin, wounds, ulcers, mucous membranes, or large body areas. Do not use it under occlusive dressing as a default. Do not use it on the breast during lactation or as a nipple salve.

Pregnancy and breastfeeding are exclusions in conservative herbal monographs: PAs can affect the fetus and can pass into milk; there is no benefit that justifies the risk. Children should not receive comfrey internally or as a casual topical for “growing pains.”

Known liver disease, a history of veno-occlusive disease, heavy alcohol use, or other PA exposures (some traditional teas, some contaminated grains in other regions) compound risk. People with cancer who have heard that allantoin “grows cells” should not experiment on tumors.

Hypersensitivity to comfrey or related plants is a stop. If a product is not clearly PA-specified for topical use, do not invent a duration.

The important interaction is with the liver itself. Drugs and herbs that induce CYP3A4 could theoretically increase conversion of PAs to toxic pyrroles; the practical advice is not to combine oral comfrey with anything, because oral comfrey should not be used. Topical short-course products still deserve disclosure if you have liver disease or take hepatotoxic medicines (including high-dose acetaminophen, some antifungals, methotrexate, and others)—not because a proven pharmacokinetic drama is fully mapped, but because the organ of concern is the same.

Alcohol plus any residual PA exposure is a poor combination. So is stacking other PA-containing plants (borage leaf, coltsfoot, some Senecio-containing folk teas) “because they’re traditional too.”

Anticoagulant cautions sometimes appear in secondary lists without a clean mechanism; the practical rule is disclosure before surgery, not because comfrey is yohimbe, but because trauma, poultices, and procedures get mixed together.

Do not combine comfrey poultice with heating pads on a possibly fractured limb as a way to avoid an X-ray. That is not a drug interaction. It is a diagnostic delay.